Finance

Beta
Lists
ORX:STO
Orexo AB
SEK 18.98
-2.27%
(-0.44) 1D
Jun 5, 5:29:30 PM GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for ORX...
Open
SEK 19.28
High
SEK 19.56
Low
SEK 18.78
Mkt. cap
666.71M
Avg. vol.
47.42K
Volume
31.54K
P/E ratio
0.75
52-wk high
SEK 43.40
52-wk low
SEK 15.42
EPS
SEK 25.33
Shares outstanding
35.13M
No. of employees
65
Open
SEK 19.28
High
SEK 19.56
Low
SEK 18.78
Mkt. cap
666.71M
Avg. vol.
47.42K
Volume
31.54K
P/E ratio
0.75
52-wk high
SEK 43.40
52-wk low
SEK 15.42
EPS
SEK 25.33
Shares outstanding
35.13M
No. of employees
65
News stories
From sources across the web
Profile
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
About Orexo AB
CEONikolaj Sørensen
Employees65
Founded1995
Headquarters-
SectorPharmaceutical industry
Websiteorexo.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
118.20M
118.70M
3.30M
5.00M
Cost of goods sold
8.40M
7.10M
2.60M
500.00K
Cost of revenue
8.40M
7.10M
2.60M
500.00K
Research and development expenses
57.20M
61.70M
55.60M
50.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
71.10M
71.90M
28.00M
37.40M
Operating expense
128.10M
132.51M
80.70M
80.20M
Total operating expenses
136.50M
139.61M
83.30M
80.70M
Operating income
-18.30M
-20.91M
-80.00M
-75.70M
Other non operating income
-500.00K
-200.00K
-200.00K
-100.00K
EBT including unusual items
-33.90M
-32.70M
-115.50M
-104.20M
EBT excluding unusual items
-34.50M
-32.71M
-93.50M
-104.50M
Income tax expense
5.90M
-2.90M
100.00K
1.00M
Effective tax rate
-17.40%
8.87%
-0.09%
-0.96%
Other operating expenses
-200.00K
-1.09M
-2.90M
-7.30M
Net income
-39.80M
-29.80M
724.80M
-133.90M
Net profit margin
-33.67%
-25.11%
21,963.64%
-2,678.00%
Earnings per share
-1.15
-
-
-
Interest and investment income
300.00K
800.00K
600.00K
4.40M
Interest expense
-12.00M
-11.30M
-12.20M
-32.90M
Net interest expenses
-11.70M
-10.50M
-11.60M
-28.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.90M
-9.61M
-46.80M
-66.90M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer